LSE company dividends information has been updated. You can find this is in the menu on any Quote page. ADVFN team.


Kromek Group Plc

0.00 (0.0%)
Share Name Share Symbol Market Type Share ISIN Share Description
Kromek Group Plc LSE:KMK London Ordinary Share GB00BD7V5D43 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 5.50 1,600,881 08:00:00
Bid Price Offer Price High Price Low Price Open Price
5.40 5.60 5.50 5.50 5.50
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Miscellaneous Metal Ores,nec 12.06 -4.92 -1.10 - 23.75
Last Trade Time Trade Type Trade Size Trade Price Currency
16:35:00 O 17 5.60 GBX

Kromek (KMK) Latest News

Kromek (KMK) Discussions and Chat

Kromek Forums and Chat

Date Time Title Posts
02/6/202313:58Kromek Group PLC6,847
05/1/202209:19Kromek Group (KMK) - Overvalued AIM mugging182

Add a New Thread

Kromek (KMK) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type

Kromek (KMK) Top Chat Posts

Top Posts
Posted at 25/5/2023 13:19 by ark87
I posted this on 11th May. This share is dodgy... very very dodgy... and honestly needs investigating...

"It’s so obvious what’s going on here it’s laughable. They have engineered a rise in the share price to sucker people into the placing and the rampers (strategic investor and his merry men) are out in full force. Once they get the placing through , the share price will collapse below 5p. EXACT same thing happened with covid detector placing."

Posted at 12/5/2023 18:22 by aqc888
Percentage of the CEOs total compensation paid regardless of performance 97.8%.


For some context compare that to the ceo of Smiths Detection who’s salary comprised of 47.8% salary and 52.2% bonuses.

Kromek share price at IPO 73p
Kromek share today. 5.6p

Smiths detection ipo 277p
Today 1663p

Anyone who thinks Kromek are going to start respecting shareholders cash need their head examined. In the words of Warren Buffett “poor managers often don’t think that much of shareholders either. The two often go hand in hand”.

Posted at 11/5/2023 11:35 by ark87
It’s so obvious what’s going on here it’s laughable. They have engineered a rise in the share price to sucker people into the placing and the rampers (strategic investor and his merry men) are out in full force. Once they get the placing through , the share price will collapse below 5p. EXACT same thing happened with covid detector placing.
Posted at 10/5/2023 15:12 by quepassa
I fully agree.

In my view, the market-makers are busting a gut to keep the price at circa 5p.

I share the same opinion as you that that the share price will collapse to 4p - or even lower.

The IMPORTANT THING to consider is that private shareholders collectively have the power to block the resolutions and do not have to suffer further egregious dilution of their shareholdings by this latest fund-raising.


Posted at 09/5/2023 20:21 by aqc888
For some context;

Pivotal year unfolding for Kromek - 18/1/22
Share price 14.5p

Winners in an uncertain world - 16/5/22
Share price 9.7p

Kromek’s record sales visibility is materially undervalued - 2/8/22
Share price 9.5p

A biological detection winner - 11/22
Share price 8.75p

This stock is about to turn world-leading technology into profit - 2/23

Analysts think this stock's share price will quadruple - 4/23
Share price 6.85p

Buy into Kromek's £7.5mn open offer of new shares - today
Share price 5p

…. It goes back way further when share price was way way higher…

“Don't worry about Kromek's revenue fall“ - 1/2019
Share price 26p

Posted at 27/4/2023 15:17 by skyship
Analysts think this stock's share price will quadruple

It has announced a company-transforming seven-year agreement highlighting its bargain share price

April 19, 2023.....By Simon Thompson

Ground-breaking seven-year agreement with a Tier One OEM
Agreement to develop next-generation CT detector technology
Positive trading update
Sedgefield-based Kromek (KMK:6.85p), a radiation detection technology company focused on the medical imaging and nuclear markets, has announced a company-transforming seven-year agreement with a top-tier original equipment manufacturer (OEM) to develop cadmium zinc telluride (CZT)-based detectors for the client’s advanced medical imaging scanners.

Following a short development period, the agreement will transition into a longer commercial supply phase. The enhanced image quality associated with the technology could enable the earlier detection of diseases, such as heart disease and cancer, thereby improving patient outcomes and increasing efficiencies within healthcare settings.

Analysts at Equity Development note that the medical imaging market is divided between computed tomography (CT) and single-photon emission CT (SPECT)-based products and is dominated by four tier-one suppliers: Phillips Medical Systems, Siemens Healthineers GmbH, Canon Medical Systems and GE Healthcare.

House broker FinnCap estimates that the CT medical imaging scanner market was worth $6.7bn in 2022, with the tier-one suppliers controlling 85 to 90 per cent of the market. Market research company Market Data Forecast estimates that the CT scanner market could be worth $7.2bn in 2023, growing to $9bn by 2028, the implication being that this could be a $10bn market by 2030.

Value of agreement to Kromek
On this basis, FinnCap calculates that the CZT-based share of the CT scanner market could be worth $2bn in 2030, assuming the new technology scanners take a 20 per cent share of the total market, suggesting an addressable market opportunity of $300mn-$400mn for a tier-one supplier. This would imply revenue to Kromek of $64mn (£51mn) in 2030, generating $26mn (£20mn) of gross profit on a margin of 40 per cent and annual cash profit of £10mn-£15mn.

Moreover, assuming the tier-one OEM converts 50 per cent of its scanners to CZT over a 10-year period, it implies that the agreement has a net present value (NPV) of £39mn-£59mn (9p to 14p a share) using discount rates of 10 to 15 per cent, respectively. In a more optimistic scenario in which the conversion rate rises to 75 per cent, the NPV of the agreement rises to £58mn-£87mn (13p to 20p a share), a hefty sum in relation to Kromek’s current market capitalisation of £28.8mn (6.85p).

The strategic value of CZT to tier-one OEMs in their next-generation diagnostic imaging development was brought into sharp focus in September 2021 when Canon acquired Kromek’s rival Redlen Technologies for a valuation of $290mn, or a multiple of 20 to 33 times its annual revenue (£ to £8.4mn) at the time. Kromek is now the only independent developer and producer of CZT-based detection systems. Equity Development has a read-across implied valuation for Kromek’s medical imaging division of £247mn (57p), or 8.5 times its current market capitalisation, based on a multiple of 25 times 2023-24 revenue estimates of £9.9mn for the unit.

Posted at 18/4/2023 11:17 by quepassa
You do need to get a handle on your petulance, cattiness and spitefulness, susie.
It's very unattractive.

On the contrary, susie! One of your posts from two years is highly pertinent.

It illustrates just how wide of the mark you were.

The share price is down a whopping 75% from 24p to 6p over that time-frame against the great optimism apparent in your post.

One notes that you have avoided commenting on your post and the share price performance.

Good attempt at deflection,susie, but it won't fool anybody.

Would you now care to comment on your post?

Posted at 08/3/2023 17:01 by mrwarrenb
I had a virtual meeting this morning with both Arnab Basu (CEO) and Paul Farquhar (CFO). Also present was Harry Chathli from Gracechurch PR.

Rather than colour this post with my own personal opinions, I’ve tried to provide an objective summary below of what we discussed. The call lasted only 30 minutes and we were only allowed to talk about publicly-available information, so apologies if your question wasn’t covered.

Share price: the company doesn't control the markets, so this is largely beyond their control. The company is back on a growth path with a strong trajectory and the drivers of its two main businesses, medical imaging and CBRN detection, are fundamentally strong.

Executive purchases of shares: “Senior management and the Board of Directors don’t have many opportunities to buy shares outside of capital raises, but whenever they can, they do.” CFO Paul Farquhar owns £5,000 worth of shares, in his wife’s name, which were worth £10,000 at the time they were purchased. Understand that shareholders are keen to see them have “skin in the game”.

Cash position: this is closely managed at all times. No cash was consumed during the H1 23 reporting period – the first time this has happened. Unable to comment about future requirements or capital raises. The company considers both debt and equity for the its financing requirements.

DARPA contract: this is coming to an end and there don’t appear to be any immediate follow-ons, but on a related note, Kromek was awarded a £5m biological threat-detection contract by the UK Government in November 2022, which will be delivered over a three-year period, and this does include an option for extended maintenance services after the initial term.

Sales: Strong revenue growth in both medical imaging and CBRN detection. The fundamentals of both sectors are strong (ageing population -> better and more cost-effective diagnostics required; governments reviewing their biosecurity strategies in the light of the Ukraine situation -> improved detection needs, especially in cities) and Kromek is now well-positioned to benefit. Unable (for confidentiality reasons) to provide any updates on the timing of any new contract wins/announcements.

Costs: the fundamental building blocks of the business are now in place and the cost base won’t continue to scale up as revenues scale up. Costs are constantly under review and the organisation is already lean. There is no wholesale cost-reduction programme planned.

China contract inventory: the inventory from the China contract, which was due to be delivered in 2020 does not have a shelf-life and will not “go bad”. It can be sold to other customers over the coming years, which would bring cash into the business and free up cash that is currently tied up in the balance sheet. China is starting to open up again now and a recovery in business there is expected. Previously, it wasn’t practical to travel there, because of the lengthy isolation periods required as a result of covid restrictions. Any future sales in the region might be direct or via a distributor.

Potential takeover target?: unable to comment on this. Could only say that, as a listed company, they are committed to remaining independent.

Engagement with shareholders: acknowledgement this could have been better and committed to holding an investor webinar/Q&A session, chaired by Harry Chathli of Gracechurch PR. No concrete timing for this, but likely to be scheduled around the results. The company welcomes visitors to its County Durham global HQ.

Overall: Dr Basu reiterated the strong, positive growth story in revenues, with 40+% gross margins. The Spectrum Dynamics deal from October 2022 continues to ramp up each quarter. Acknowledge shareholders’ frustration with the share price performance but feel this is largely outside their control. No forecasts or updates about when the business might become profitable.

Thanks again to everyone on the board who submitted questions in advance. The more searching ones were batted away or couldn't be answered, because of confidentiality reasons, but senior management is most definitely aware now (if it wasn't before) of shareholders' concerns and expectations.

Posted at 10/8/2022 03:36 by ark87
The shareprice was down until IC tipped it (again). Unfortunately as you can see from KMK share price performance since inception (51p to to 14p over 9 years) will be short lived unless some game changing news is on horizon which at this point seems doubtful.
Posted at 05/8/2022 13:52 by aqc888
It’s all a bit mysterious with Kromek. I find it a very interesting one to watch. However the deeds of the CEO speak far louder than his words throughout the history of Kromek. By that I mean his purchase of shares remains very little, as the share price collapses he should take the opportunity to buy a significant amount - that’s if he believes his view of how great things are going to be.

The share ownership of the ceo has tipped my view into believing the worst. It’s with great disappointment I sell a big chunk of my remaining Kromek, especially as someone who once believed so much in Kromek I allocated 10% of my portfolio in it (reduced to 2% at 16p).

The CEOs decision not to invest has been the correct one looking at Kromeks history. His continued decision not to invest would seem to be the clearest indication of where Kromeks future lies and whether the current share price weakness is a bargain or not. He should lead with his actions as the share price collapses. That’s just my personal view of what a founder & CEO should do if his share price is collapsing and he genuinely believes the market has got it wrong. Perhaps a bit of an unfair view…

Kromek share price data is direct from the London Stock Exchange
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: +44 (0) 203 8794 460 |

V: D: 20230604 15:21:02